Jun 24

Endurance RP Limited: A New Name, A New Perspective - Eye on China’s fertility and longevity market


JUN 24

Endurance RP Limited: A New Name, A New Perspective - Eye on China’s fertility and longevity market


MAY 20

Regent Pacific’s Deep Longevity announces partnership with LifeHub and LifeClinic in Hong Kong


MAY 11

Regent Pacific’s Unrealised Gain in Venturex Resources Limited Increased to US$10.74 million


APR 01

Regent Pacific Receives HK$24 million After Clinical Trial Approval For Fortacin™ Has Been Obtained


MAR 30

Regent Pacific Announces 2020 Annual Results, Significant Milestones Achieved on the Commercialisation of Fortacin™ and Business Expansion


FEB 09

Regent Pacific’s Strategic Partner Obtains Clinical Trial Approval for Fortacin™


JAN 18

Regent Pacific Announces the Successful Launch of Fortacin™ in Hong Kong, Upcoming Launches in Taiwan and Macau and Related Business Updates


JAN 11

Regent Pacific Announces Key Research Findings on Fortacin™ – Encouraging Step Towards the Commercialization of Fortacin™ in the US


JAN 04

Regent Pacific Announces Key Progresses on Fortacin™ / Senstend™ – Solution to Premature Ejaculation